If approved, Lucemyra (lofexidine) would be the first non-opioid drug approved to treat the symptoms of opioid withdrawal.
If approved, Lucemyra (lofexidine) would be the first non-opioid drug approved to treat the symptoms of opioid withdrawal.
A new study analyzes the characteristics of chronic opioid use claims, while also examining opioid weaning data.
Apadaz oral tablets were approved for the short-term management of acute pain, at no more than 14 days of use.
The number of opioid-dependent injured workers in the Ohio workers' comp system fell 19% in 2017.
Forty-one states and over 200 cities and counties claim drug makers deceived patients and doctors regarding opioid safety and addiction risks.
Senna Laxative bottles were found to contain NSAIDs, while 55 lots of compounded drugs face questionable sterility.
A visual depiction of how opioid side effects can cascade across the body.
When taken in excessive doses, the anti-diarrhea drug loperamide can mimic opioid euphoria, and toxicity events and deaths are on the rise.
Despite decreases in prescribing rates, the opioid epidemic claims more lives than ever before, partially due to synthetic formulations.
